Intrapleural gene therapy for alpha-1 antitrypsin deficiency-related lung disease

Katie M. Stiles, Dolan Sondhi, Stephen M. Kaminsky, Bishnu P. De, Jonathan B. Rosenberg, Ronald Crystal

Research output: Contribution to journalReview article

Abstract

Alpha-1 antitrypsin deficiency (AATD) manifests primarily as early-onset emphysema caused by the destruction of the lung by neutrophil elastase due to low amounts of the serine protease inhibitor alpha-1 antitrypsin (AAT). The current therapy involves weekly intravenous infusions of AAT-derived from pooled human plasma that is efficacious, yet costly. Gene therapy applications designed to provide constant levels of the AAT protein are currently under development. The challenge is for gene therapy to provide sufficient amounts of AAT to normalize the inhibitor level and anti-neutrophil elastase capacity in the lung. One strategy involves administration of an adeno-associated virus (AAV) gene therapy vector to the pleural space providing both local and systemic production of AAT to reach consistent therapeutic levels. This review focuses on the strategy, advantages, challenges, and updates for intrapleural administration of gene therapy vectors for the treatment of AATD.

Original languageEnglish
Pages (from-to)244-257
Number of pages14
JournalChronic Obstructive Pulmonary Diseases
Volume5
Issue number4
DOIs
Publication statusPublished - 1 Jan 2018

Fingerprint

alpha 1-Antitrypsin Deficiency
alpha 1-Antitrypsin
Genetic Therapy
Lung Diseases
Leukocyte Elastase
Lung Volume Measurements
Dependovirus
Serine Proteinase Inhibitors
Emphysema
Intravenous Infusions
Therapeutics
Autosomal Recessive alpha-1-Antitrypsin Deficiency
Lung
Proteins

Keywords

  • Adeno-asssociated virus vectors
  • Alpha-1 antitrypsin deficiency
  • Gene therapy

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Intrapleural gene therapy for alpha-1 antitrypsin deficiency-related lung disease. / Stiles, Katie M.; Sondhi, Dolan; Kaminsky, Stephen M.; De, Bishnu P.; Rosenberg, Jonathan B.; Crystal, Ronald.

In: Chronic Obstructive Pulmonary Diseases, Vol. 5, No. 4, 01.01.2018, p. 244-257.

Research output: Contribution to journalReview article

Stiles, Katie M. ; Sondhi, Dolan ; Kaminsky, Stephen M. ; De, Bishnu P. ; Rosenberg, Jonathan B. ; Crystal, Ronald. / Intrapleural gene therapy for alpha-1 antitrypsin deficiency-related lung disease. In: Chronic Obstructive Pulmonary Diseases. 2018 ; Vol. 5, No. 4. pp. 244-257.
@article{9d0939fae1ec47ff97400e9a3ca1701e,
title = "Intrapleural gene therapy for alpha-1 antitrypsin deficiency-related lung disease",
abstract = "Alpha-1 antitrypsin deficiency (AATD) manifests primarily as early-onset emphysema caused by the destruction of the lung by neutrophil elastase due to low amounts of the serine protease inhibitor alpha-1 antitrypsin (AAT). The current therapy involves weekly intravenous infusions of AAT-derived from pooled human plasma that is efficacious, yet costly. Gene therapy applications designed to provide constant levels of the AAT protein are currently under development. The challenge is for gene therapy to provide sufficient amounts of AAT to normalize the inhibitor level and anti-neutrophil elastase capacity in the lung. One strategy involves administration of an adeno-associated virus (AAV) gene therapy vector to the pleural space providing both local and systemic production of AAT to reach consistent therapeutic levels. This review focuses on the strategy, advantages, challenges, and updates for intrapleural administration of gene therapy vectors for the treatment of AATD.",
keywords = "Adeno-asssociated virus vectors, Alpha-1 antitrypsin deficiency, Gene therapy",
author = "Stiles, {Katie M.} and Dolan Sondhi and Kaminsky, {Stephen M.} and De, {Bishnu P.} and Rosenberg, {Jonathan B.} and Ronald Crystal",
year = "2018",
month = "1",
day = "1",
doi = "10.15326/jcopdf.5.4.2017.0160",
language = "English",
volume = "5",
pages = "244--257",
journal = "Chronic Obstructive Pulmonary Diseases",
issn = "2372-952X",
publisher = "COPD Foundation",
number = "4",

}

TY - JOUR

T1 - Intrapleural gene therapy for alpha-1 antitrypsin deficiency-related lung disease

AU - Stiles, Katie M.

AU - Sondhi, Dolan

AU - Kaminsky, Stephen M.

AU - De, Bishnu P.

AU - Rosenberg, Jonathan B.

AU - Crystal, Ronald

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Alpha-1 antitrypsin deficiency (AATD) manifests primarily as early-onset emphysema caused by the destruction of the lung by neutrophil elastase due to low amounts of the serine protease inhibitor alpha-1 antitrypsin (AAT). The current therapy involves weekly intravenous infusions of AAT-derived from pooled human plasma that is efficacious, yet costly. Gene therapy applications designed to provide constant levels of the AAT protein are currently under development. The challenge is for gene therapy to provide sufficient amounts of AAT to normalize the inhibitor level and anti-neutrophil elastase capacity in the lung. One strategy involves administration of an adeno-associated virus (AAV) gene therapy vector to the pleural space providing both local and systemic production of AAT to reach consistent therapeutic levels. This review focuses on the strategy, advantages, challenges, and updates for intrapleural administration of gene therapy vectors for the treatment of AATD.

AB - Alpha-1 antitrypsin deficiency (AATD) manifests primarily as early-onset emphysema caused by the destruction of the lung by neutrophil elastase due to low amounts of the serine protease inhibitor alpha-1 antitrypsin (AAT). The current therapy involves weekly intravenous infusions of AAT-derived from pooled human plasma that is efficacious, yet costly. Gene therapy applications designed to provide constant levels of the AAT protein are currently under development. The challenge is for gene therapy to provide sufficient amounts of AAT to normalize the inhibitor level and anti-neutrophil elastase capacity in the lung. One strategy involves administration of an adeno-associated virus (AAV) gene therapy vector to the pleural space providing both local and systemic production of AAT to reach consistent therapeutic levels. This review focuses on the strategy, advantages, challenges, and updates for intrapleural administration of gene therapy vectors for the treatment of AATD.

KW - Adeno-asssociated virus vectors

KW - Alpha-1 antitrypsin deficiency

KW - Gene therapy

UR - http://www.scopus.com/inward/record.url?scp=85057307488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057307488&partnerID=8YFLogxK

U2 - 10.15326/jcopdf.5.4.2017.0160

DO - 10.15326/jcopdf.5.4.2017.0160

M3 - Review article

AN - SCOPUS:85057307488

VL - 5

SP - 244

EP - 257

JO - Chronic Obstructive Pulmonary Diseases

JF - Chronic Obstructive Pulmonary Diseases

SN - 2372-952X

IS - 4

ER -